Patents by Inventor Andrew Philip Crew

Andrew Philip Crew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fused Bicyclic mTor Inhibitors
    Publication number: 20090163468
    Abstract: Compounds represented by Formula (I) or a pharmaceutically acceptable salt thereof, are inhibitors of mTOR and useful in the treatment of cancer.
    Type: Application
    Filed: December 2, 2008
    Publication date: June 25, 2009
    Inventors: Xin Chen, Heather Coate, Andrew Philip Crew, Han-Qing Dong, Ayako Honda, Mark Joesph Mulvihill, Paula A.R. Tavares, Jing Wang, Douglas S. Werner, Kristen Michelle Mulvihill, Kam W. Siu, Bijoy Panicker, Apoorba Bharadwaj, Lee D. Arnold, Meizhong Jin, Brian Volk, Qinghua Weng, James David Beard
  • 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors
    Publication number: 20090118499
    Abstract: Compounds of the formula and pharmaceutically acceptable salts thereof, wherein X1, X2, X3, X4, X5, X6, X7, R1, and Q1 are defined herein, inhibit the IGF-1R enzyme and are useful for the treatment and/or prevention of hyperproliferative diseases such as cancer, inflammation, psoriasis, allergy/asthma, disease and conditions of the immune system, disease and conditions of the central nervous system.
    Type: Application
    Filed: October 3, 2008
    Publication date: May 7, 2009
    Inventors: Lee D. Arnold, Heather Coate, Andrew Philip Crew, Hanqing Dong, Kenneth Foreman, Ayako Honda, Radoslaw Laufer, An-Hu Li, Kristen Michelle Mulvihill, Mark Joseph Mulvihill, Anthony Nigro, Bijoy Panicker, Arno G. Steinig, Quinghua Weng, Douglas S. Werner, Michael J. Wyle, Tao Zhang, Cara Cesario, Yingchuan Sun
  • Pyrrolo[2,3-D]imidazoles for the treatment of hyperproliferative disorders
    Patent number: 7498354
    Abstract: or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors and cancers.
    Type: Grant
    Filed: March 30, 2006
    Date of Patent: March 3, 2009
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Andrew Philip Crew, Bijoy Panicker, Han-Qing Dong
  • N-substituted benzimidazoyl c-Kit inhibitors and combinatorial benzimidazole library
    Patent number: 7419995
    Abstract: Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, are useful in the treatment of tumors. Combinatorial libraries composed of compounds represented by Formula (I) or benzimidazole compounds represented by Formula (II): are useful in providing compounds to assay for such therapeutically useful compounds.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: September 2, 2008
    Assignee: OSI Pharmaceuticals, Inc.
    Inventors: Andrew Philip Crew, Matthew Cox, Radoslaw Laufer, Neil Anthony Pegg, Colin Peter Sambrook Smith, Yingchuan Sun, Robin David Wilkes, Jonathan Williams